Here are Thursday's biggest analyst calls: Nvidia, SpaceX, Tesla, Ferrari, Meta, Apple, AMD, Yum & more

Wall Street's Thursday calls skewed bullish, with upgrades or Buy/Overweight initiations spanning AI infrastructure, semiconductors, biotech, energy and transportation. Notable actions included JPMorgan upgrading Meta to Overweight and raising its target to $820 from $640, Piper Sandler initiating Nvidia, Broadcom, Arm and AMD at Overweight amid accelerator demand estimated at 2x supply, and Wells Fargo upgrading Synopsys on accelerating AI-driven momentum. Offsetting the broadly constructive tone, Morgan Stanley downgraded Nike to Underweight, citing overly optimistic growth assumptions—particularly in China—and valuation concerns.

Analysis

The concentrated bullishness across AI compute, memory, design software and GPU-cloud infrastructure is more important than any individual rating change: it reinforces a capex-duration narrative rather than a one-quarter accelerator trade. The cleanest second-order beneficiary is SNPS, where rising chip complexity and custom-silicon proliferation expand recurring EDA/tool demand without requiring the inventory and supply-chain execution embedded in NVDA, AVGO, AMD or SKHY. Near term, however, simultaneous sell-side enthusiasm raises crowded-positioning risk in the semiconductor complex; upside needs forward revenue revisions, not further target-price increases.

META is the more differentiated large-cap AI expression because incremental product monetization can lift ad load, conversion and engagement while its existing distribution absorbs much of the model-development cost. That contrasts with TSLA, where autonomous-driving optionality remains principally constrained by jurisdiction-by-jurisdiction authorization; the market should apply a materially higher probability discount to revenue timing there. A regulatory setback or delayed deployment schedule would widen META/TSLA relative performance quickly, while Meta-specific risk is a capex step-up that outpaces ad-revenue conversion over the next two earnings reports.

The transport and industrial calls imply an early-cycle North American recovery, but the risk/reward differs sharply by operating leverage. XPO and SAIA need a sustained LTL pricing/mix improvement to justify upside, whereas PCAR and KNX require a broader freight-rate and equipment-order recovery; the latter group is more exposed if macro data soften. In consumer, NKE remains a cleaner short than a long in YUM or CASY: channel fragmentation and a slower China recovery can keep earnings expectations resetting even if the broader discretionary tape improves.

Biotech initiations in ABVX, RVMD and KYMR are not independently investable without catalyst calendars, cash-runway analysis and probability-adjusted trial assumptions. Treat rating-driven strength as liquidity rather than validation until clinical data, enrollment updates, or regulatory milestones provide a falsifiable fundamental catalyst.

Key Decisions for Investors

• Initiate a 1-3 month long SNPS / short SMH pair, sized beta-neutral: SNPS offers AI-capex exposure with less hardware supply risk. Add only if its upcoming outlook supports consensus forward revenue/EPS; exit on a guidance shortfall or if the relative spread closes 8-10%.
• Run long META / short TSLA through the next 1-2 earnings cycles, using equal-dollar exposure and a 10-12% stop on the relative spread. The thesis is monetizable AI distribution versus regulatory-gated autonomy; cover if Tesla receives material multi-jurisdiction commercialization approvals or Meta guides capex materially above revenue growth.
• Maintain a tactical underweight/short NKE versus XLY for 3-6 months. Consensus recovery assumptions remain vulnerable to another China or wholesale-channel reset; cover on evidence of sustained full-price sell-through and a credible upward revision to FY revenue growth.
• Watch XPO and SAIA rather than chase rating-driven moves; initiate only after monthly freight data show sequential pricing improvement and management commentary confirms margin conversion. A weak industrial-production or freight-volume print would invalidate the rate-reset setup.
• Do not initiate ABVX, RVMD, or KYMR on coverage launches alone. Create event alerts around trial readouts, FDA interactions and financing needs; position size should be determined by cash runway and implied probability of success, currently missing from the dataset.